Comparison of treatment and outcomes in participants with and without type 2 diabetes mellitus
| No diabetes (n=16) | Type 2 diabetes (n=4) | p Value | |
| Study entry | |||
| Entry CBG (mmol/l) | 8.7 (6.5–12.1) | 11.9 (8.7–17.7) | 0.211 |
| Weight (kg) | 6 male: 86±25 | 4 male: 93±26 | 0.762 |
| 10 female: 55±13 | – | – | |
| BMI (kg/m2) | 6 male: 31.1±10 | 4 male: 32.0±9.3 | 1.0 |
| 10 female: 22.4±5.9 | – | – | |
| Treatment | |||
| Intravenous insulin (IU/24 h) | 6 male: 74 (43–93) | 4 male: 116 (57–146) | 0.257 |
| 10 female: 36 (20–66) | – | ||
| Subcutaneous insulin (IU/24 h) | 5 male: 67 (34–81) | 4 male: 90 (26–118) | 0.571 |
| 7 female: 20 (16–53) | – | ||
| Safety | |||
| CBG <2.2 mmol/l (% measurements) | 0.2% | 0% | 0.674 |
| CBG ≤3.3 mmol/l (%) | 4.5% | 2.0% | 0.071 |
| Efficacy | |||
| Study CBG (mmol/l) | 5.8 (5.3–6.3) | 6.9 (6.2–8.0) | 0.022 |
| 06:00 CBG (mmol/l) | 4.7 (4.2–5.2) | 6.1 (5.8–6.2) | 0.004 |
| Percentage of CBG measurements in target range | 43 | 27 | 0.000 |
| Percentage of time CBG in target range | 44±12 | 28±9 | 0.024 |
| Hyperglycaemic index | 1.0 (0.6–1.2) | 1.7 (1.6–2.2) | 0.005 |
| Glycaemic variability (mmol/l) | 2.7±0.7 | 3.1±0.7 | 0.395 |
CBG, capillary blood glucose.